The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy
This Phase IV interventional trial (n=13; terminated) aimed to assess the pain-reducing effects of ketamine and methadone after lumbar laminectomy.
Detailed Description
Randomized, quadruple‑masked, parallel Phase IV trial comparing IV ketamine, IV methadone, and their combination for intraoperative use to reduce postoperative pain after lumbar laminectomy.
Primary aim was to evaluate whether intraoperative ketamine (0.5 mg/kg bolus plus 5 µg/kg/min infusion), methadone (0.2 mg/kg preinduction), or their combination reduces postoperative opioid requirements and improves recovery outcomes.
Study Protocol
Preparation
Dosing
Integration
Study Arms & Interventions
Ketamine
active comparatorIV ketamine bolus during induction (0.5 mg/kg) with intraoperative IV ketamine infusion (5 µg/kg/min).
Interventions
- Ketamine0.5 mg/kgvia IV• intraoperative• 1 doses total
Bolus 0.5 mg/kg during induction with infusion 5 µg/kg/min intraoperatively.
Methadone
active comparatorSingle IV methadone dose preinduction (0.2 mg/kg).
Interventions
- Placebo0.2 mg/kgvia IV• preinduction single dose• 1 doses total
Methadone 0.2 mg/kg IV preinduction (encoded under placebo compound reference as methadone is not in compound list).
Ketamine + methadone
experimentalCombination: methadone 0.2 mg/kg preinduction plus ketamine bolus 0.5 mg/kg and infusion 5 µg/kg/min intraoperatively.
Interventions
- Ketamine0.5 mg/kgvia IV• intraoperative• 1 doses total
Bolus 0.5 mg/kg during induction with infusion 5 µg/kg/min intraoperatively.
- Placebo0.2 mg/kgvia IV• preinduction single dose• 1 doses total
Methadone 0.2 mg/kg IV preinduction (encoded under placebo compound reference).
Participants
Inclusion Criteria
- Inclusion Criteria:
- 18 - 80 years old of either gender
- Scheduled for elective lumbar laminectomy
Exclusion Criteria
- Exclusion Criteria:
- American Society of Anesthesiologists (ASA) IV and above
- Intolerance, allergy, or contraindication to use of any medications used in this study
- Significant coronary artery disease (abnormal stress test, myocardial infarction within the last 3 months)
- Increased intraocular pressure (e.g., untreated glaucoma)
- Uncontrolled hypertension (BP > 140/90)
- Sleep apnea and currently on continuous positive airway pressure (CPAP)
- Increased intracranial pressure or clinical signs thereof
- History of intracranial surgery, stroke, or brain aneurysm
- Cardiac arrhythmias particularly prolonged QT syndrome
- Drugs known to cause prolonged QT: class IA antiarrhythmics (quinidine, procainamide, disopyramide), class III antiarrhythmics (sotalol, dofetilide, ibutilide, amiodarone), haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic antidepressants
- Individuals with significant psychological disorders including: schizophrenia, mania, bipolar disorder or psychosis
- Pregnant or lactating women
- Emergent laminectomy
- Those already receiving ketamine or methadone prior to surgery
- Morbid obesity (BMI > 40 kg/m2) AND/OR weight > 150 kg
- Chronic renal failure (creatinine > 2.0 mg/dL)
- Liver failure e.g., active cirrhosis
- Alcohol or substance abuse within the past 3 months
- Uncorrected hypokalemia, hypomagnesemia, hypocalcemia
- Chronic obstructive pulmonary disease (COPD)/Hypercarbia
- Restrictive lung disease (pulmonary fibrosis, myasthenia gravis)
- Congestive heart failure
- Thyroid disease
- Organ transplant patients
- Drugs/substances known to inhibit methadone metabolism: macrolide antibiotics e.g., erythromycin, cimetidine, astemizole, voriconazole, grapefruit juice
Study Details
- StatusTerminated
- PhasePhase IV
- Typeinterventional
- DesignRandomizedquadruple Blind
- Target Enrollment13 participants
- TimelineStart: 2013-02-01End: 2023-01-31
- Compounds
- Topic